Why We Exist
We are dedicated to developing groundbreaking antibody therapies to address the world's most challenging diseases.
We are at the forefront of antibody drug development,
harnessing cutting-edge science to create life-saving treatments.
Through advanced biopharmaceutical research,
we develop groundbreaking antibody therapies that revolutionize patient care.
We are at the forefront of antibody drug development, harnessing cutting-edge science to create life-saving treatments.
Through advanced biopharmaceutical research, we develop groundbreaking antibody therapies that revolutionize patient care.
We are dedicated to developing groundbreaking antibody therapies to address the world's most challenging diseases.
Harnessing the potential of antibodies to develop innovative next-generation therapies.
2025-03-19
FNCT, 新접근 ‘CSF3 타깃’ IPF 도전 “자신하는 이유”2025-03-19
2025-02-20
FNCT, ‘ICAM1-EGFR’ TNBC 전이촉진 ”新기전” 논문2025-02-20
2025-02-06
"새해" 1월 비상장투자, 4곳 613억.."순조로운 출발"2025-02-06
2025-01-20
FNCT 바이오텍, 시리즈A 60억..IPF ‘CSF3 항체’ 개발2025-01-20
2024-11-21
삼중음성 유방암 치료 길 열릴까... 신약 개발 실마리 찾아낸 바이오기업2024-11-21
2024-11-20
암젠코리아‧보산진, ‘2024 골든티켓’ 최종 우승 기업 발표2024-11-20
2023-10-10
섬유증 치료제 개발사 FNCT, 20억 투자 유치2023-10-10
2022-12-06
데일리파트너스, 바이오 혹한기 '길잡이' 역할 나섰다2022-12-06
2022-11-07
[비바100] "폐섬유증 환자에 희망… 치료제시장 '게임 체인저'될 것"2022-11-07
2022-07-05
FNCT, IPF 타깃 '사이토카인 저해제' 초기결과 공개2022-07-05
2022-06-30
투심 위축됐지만...유망 바이오텍 9개사 VC 눈도장2022-06-30
2022-05-20
진영우 FNCT 대표 "폐 섬유증 치료 게임 체인저 목표"2022-05-20
2022-05-09
데일리파트너스, 유전공학 기반 신약 개발 FNCT '마중물'2022-05-09
2022-05-09
데일리파트너스, 루키 'FNCT·라세미아' 팁스 보낸다2022-05-09
We are dedicated to developing groundbreaking antibody therapies
to address the world's most challenging diseases.
Harnessing the potential of antibodies
to develop innovative next-generation therapies.
2025-03-19
FNCT, 新접근 ‘CSF3 타깃’ IPF 도전 “자신하는 이유”2025-03-19
2025-02-20
FNCT, ‘ICAM1-EGFR’ TNBC 전이촉진 ”新기전” 논문2025-02-20
2025-02-06
"새해" 1월 비상장투자, 4곳 613억.."순조로운 출발"2025-02-06
2025-01-20
FNCT 바이오텍, 시리즈A 60억..IPF ‘CSF3 항체’ 개발2025-01-20
2024-11-21
삼중음성 유방암 치료 길 열릴까... 신약 개발 실마리 찾아낸 바이오기업2024-11-21
2024-11-20
암젠코리아‧보산진, ‘2024 골든티켓’ 최종 우승 기업 발표2024-11-20
2023-10-10
섬유증 치료제 개발사 FNCT, 20억 투자 유치2023-10-10
2022-12-06
데일리파트너스, 바이오 혹한기 '길잡이' 역할 나섰다2022-12-06
2022-11-07
[비바100] "폐섬유증 환자에 희망… 치료제시장 '게임 체인저'될 것"2022-11-07
2022-07-05
FNCT, IPF 타깃 '사이토카인 저해제' 초기결과 공개2022-07-05
2022-06-30
투심 위축됐지만...유망 바이오텍 9개사 VC 눈도장2022-06-30
2022-05-20
진영우 FNCT 대표 "폐 섬유증 치료 게임 체인저 목표"2022-05-20
2022-05-09
데일리파트너스, 유전공학 기반 신약 개발 FNCT '마중물'2022-05-09
2022-05-09
데일리파트너스, 루키 'FNCT·라세미아' 팁스 보낸다2022-05-09
fnct@fnctbiotech.com
Headquarter/R&D Center
Chungmuro New Building Rm 201/226, 2, Toegye-ro 36-gil, Jung-gu, Seoul, Republic of Korea
Virginia Office
12020 Sunrise Valley Drive, Suite 100, Reston, VA 20191, USA
Copyright ⓒ FNCT BIOTECH All Rights Reserved.
| E-mail | fnct@fnctbiotech.com |
| Headquarter/R&D Center | Chungmuro New Building Rm 201/226, 2, Toegye-ro 36-gil, Jung-gu, Seoul, Republic of Korea |
| Virginia Office | 12020 Sunrise Valley Drive, Suite 100, Reston, VA 20191, USA |
Copyright ⓒ FNCT BIOTECH All Rights Reserved.